Biotech down again in 3Q19

Winners, losers by market cap tier in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion.

Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10 billion saw median losses of 9%.

However, one third of the $10 billion-plus companies had gains, led by Seattle Genetics Inc. (NASDAQ:SGEN), which rose 30% on the quarter after a slate of positive news. In mid-September, Seattle Genetics and partner Astellas Pharma Inc. (Tokyo:4503) said FDA accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or metastatic urothelial cancer; the product has a PDUFA date of March 15, 2020.

The company also unveiled positive data for

Read the full 1123 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE